Table III.
Group I: patients with and without left ventricle remodeling R (+) vs. R (–)
| Parameter | Group I R (+) | Group I R (–) | Value of p |
|---|---|---|---|
| Baseline characteristics: | |||
| Age | 61.48 ±12.1 | 64.65 ±11.2 | 0.35 |
| Females/males | 2 (3%)/15 (24%) | 14 (22%)/32 (51%) | 0.19 |
| Smoking | 8 (47%) | 23 (50%) | 0.12 |
| Diabetes | 5 (29%) | 9 (19%) | 0.49 |
| Arterial hypertension | 11 (65%) | 31 (67%) | 0.84 |
| Pharmacotherapy: | |||
| Acetylsalicylic acid | 17 (100%) | 46 (100%) | 1.0 |
| Clopidogrel | 17 (100%) | 46 (100%) | 1.0 |
| β-Blockers | 17 (100%) | 46 (100%) | 1.0 |
| ACE-I/ARB | 16 (94%) | 42 (91%) | 0.72 |
| Statins | 17 (100%) | 46 (100%) | 1.0 |
| Infarct-related artery: | |||
| Left anterior descending | 4 | 17 | 0.37 |
| Right coronary artery | 8 | 20 | 1.0 |
| Circumflex artery | 5 | 9 | 0.49 |
| Coronary artery disease: | |||
| 1-vessel CAD | 3 (18%) | 18 (39%) | 0.14 |
| 2-vessel CAD | 8 (47%) | 13 (28%) | 0.23 |
| 3-vessel CAD | 6 (35%) | 15 (33%) | 1.0 |
| STEMI anterior | 3 | 8 | 1.0 |
| STEMI inferior | 7 | 20 | 1.0 |
| STEMI lateral | 1 | 1 | 0.47 |
| NSTEMI | 6 | 17 | 1.0 |
| Killip class | 1.17 ±0.4 | 1.41 ±0.4 | 0.31 |
| Time to reperfusion | 15 ±21.5 | 8 ±12.6 | 0.03 |
| TIMI 3 | 17 (100%) | 46 (100%) | 1.0 |
| Stent implantation | 17 (100%) | 46 (100%) | 1.0 |
CAD – coronary artery disease, ACE-I – angiotensin-converting enzyme inhibitors, ARB – angiotensin receptor blockers, STEMI – ST elevation myocardial infarction, TIMI – thrombolysis in myocardial infarction